The case for & against
Bull & Bear analysis
Bearish
Evogene Ltd. (NASDAQ: EVGN) is a biotechnology company that operates at the intersection of pharmaceuticals and agricultural technology, focusing on utilizing advanced computational chemistry and artificial intelligence (AI) through its proprietary Campus AI platform. The company is pivoting towards high-value segments in drug discovery and agricultural products as it seeks to streamline operations and reduce costs, positioning itself amid a transformative landscape within these sectors. Its strategic direction emphasizes an AI-driven approach, aiming for valuable engagements in drug development and innovative agrochemical solutions.
Bull says
- ↑Operating expenses down from $22M to $13.8M in 2025
- ↑Q2 2026 net loss narrowed to $1.8M, reflecting cost discipline
- ↑$16M cash after LaviBio sale funds AI investments
- ↑Six active drug development collaborations target near-term revenues
- ↑Analysts raised earnings forecasts, indicating bullish sentiment
- ↑Proprietary Campus AI platform provides a distinct competitive moat
Bear says
- ↓H1 2026 revenue fell to $0.7M from $2.9M a year ago
- ↓Negative earnings yield and low profitability highlight inefficiency
- ↓Elevated short interest reflects market skepticism
- ↓Heavy reliance on collaborations risks stalled development
- ↓Weak growth outlook may limit long-term revenue expansion
- ↓Geopolitical instability and complex regulations could delay progress
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-20-2026bullish
Transcript signals
Bull points
- the new avenue the company is focusing on, the board is standing behind management.
- we are expecting to see a continued decline in the company expenses.
- I believe in all different expense item, R&D, business development, marketing, and sales, and also in the G&A.
Bear points
- The net loss for the first half of 2025 was approximately $7.7 million compared to approximately $9.8 million in the same period last year. The $2.1 million decrease in net loss was primarily due to decreased operating expenses and increased financing income, net, partially offset by the increased loss from operations held for sales, net, and reduced revenues.
- total operating expenses net for the first half of 2025 were approximately $7.7 million, compared to approximately $11.1 million in the same period last year. This significant decrease is mainly attributed to the reduced level of activity in our subsidiaries.
- In the second quarter, we began a streamlining process at Biomica, which included a significant workforce reduction and organizational change at the management level.
Read full transcript analysis ›